CHIMERIC THERAPEUTICS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.017 AUD | +6.25% |
|
-5.56% | -51.43% |
| May. 22 | Chimeric Therapeutics' First-in-Human CHM CDH17 Study Opens for Enrollment; Shares Up 4% | MT |
| May. 20 | Chimeric Therapeutics Receives Ethics Approval for CHM CDH17 Phase 1/2 Clinical Trial | MT |
Valuation
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 95.95 | 39.13 | 19.25 | 14.67 | - |
| Enterprise Value (EV) 1 | 73.54 | 20.74 | 19.25 | 14.67 | 14.67 |
| P/E ratio | -3.76 x | -2.27 x | -0.65 x | - | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | -6.73 x | -3.04 x | -0.68 x | -0.61 x | -0.56 x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 330,860 | 425,278 | 506,686 | 862,722 | - |
| Reference price 2 | 0.2900 | 0.0920 | 0.0380 | 0.0170 | 0.0170 |
| Announcement Date | 8/31/21 | 8/30/22 | 8/31/23 | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA 1 | -14.26 | -12.88 | -28.52 | -24 | -26 |
| EBIT 1 | -15.11 | -13.83 | -24.66 | -13.3 | -21.1 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -15.11 | -14.46 | -25.41 | -13.3 | -21.1 |
| Net income 1 | -15.11 | -14.62 | -25.5 | -13.4 | -21.2 |
| Net margin | - | - | - | - | - |
| EPS 2 | -0.0771 | -0.0406 | -0.0589 | - | - |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 8/31/21 | 8/30/22 | 8/31/23 | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 S2 | 2024 S1 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 1.55 | - | - | - | - |
| EBITDA | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| EPS | - | - | - | -0.0275 | -0.0314 | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/30/22 | 11/28/22 | 2/28/23 | 2/28/23 | 8/31/23 | 2/28/24 |
1AUD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | 22.4 | 18.4 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | 5.31 | 0.58 | - | 0.05 | 0.05 |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 8/31/21 | 8/30/22 | 8/31/23 | - | - |
1AUD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.017
AUD
Average target price
0.15
AUD
Spread / Average Target
+782.35%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -51.43% | 9.66M | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +3.23% | 22.78B | |
| -10.44% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- CHM Stock
- Financials Chimeric Therapeutics Limited
